SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549-1004
FORM 8-K/A
(Amendment No.1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 31, 2002
------------
Commission File Number 0-27756
Alexion Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 13-3648318
----------- -----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
352 Knotter Drive, Cheshire, Connecticut 06410
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
(203) 272-2596
----------------------------------------------------
(Registrant's telephone number, including area code)
Not Applicable
-------------------------------------------------------------
(Former name or former address, if changed since last report)
================================================================================
Pursuant to this Form 8-K/A, the registrant amends "Item 4. Changes in
Registrant's Certifying Accountant" of Form 8-K Current Report dated May
31, 2002 to clarify in the sixth paragraph that PricewaterhouseCoopers
commenced its engagement on May 31, 2002.
================================================================================
Item 4. Changes in Registrant's Certifying Accountant.
On May 29, 2002, Alexion Pharmaceuticals, Inc. ("the Company") decided to no
longer engage Arthur Andersen LLP ("Arthur Andersen" or "AA") as the Company's
independent public accountants. This determination followed the Company's
decision to seek proposals from other independent accountants to audit the
Company's consolidated financial statements for the year ending July 31, 2002.
The decision not to renew the engagement of AA was made by the Board of
Directors of the Company based upon a recommendation of its Audit Committee.
Arthur Andersen's reports on the Company's consolidated financial statements for
each of the years ended July 31, 2001 and 2000 did not contain an adverse
opinion or disclaimer of opinion, nor were they qualified or modified as to
uncertainty, audit scope or accounting principles.
During the years ended July 31, 2001 and 2000 and through the date of this
Current Report, there were no disagreements between the Company and Arthur
Andersen on any matter of accounting principle or practice, financial statement
disclosure, or auditing scope or procedure which, if not resolved to Arthur
Andersen's satisfaction, would have caused it to make reference to the subject
matter in connection with its report on the Company's consolidated financial
statements for such years; and there were no reportable events as defined in
Item 304(a)(1)(v) of Regulation S-K.
The Company provided Arthur Andersen with a copy of the foregoing disclosures.
Attached as Exhibit 16.1 is a copy of Arthur Andersen's letter, dated May 31,
2002, stating its agreement with such statements.
The Board of Directors, based upon a recommendation of its Audit Committee, will
engage PricewaterhouseCoopers LLP as its independent auditors to audit the
Company's consolidated financial statements for the year ending July 31, 2002.
PricewaterhouseCoopers will commence its engagement on May 31, 2002 with the
review of the Company's financial statements for the fiscal third quarter ended
April 30, 2002.
During the two most recent fiscal years ended July 31, 2001 and 2000 and through
May 31, 2002, the Company has not consulted with PricewaterhouseCoopers LLP
regarding either (i) the application of accounting principles to a specified
transaction, either completed or proposed; or the type of audit opinion that
might be rendered on the Company's consolidated financial statements, and
neither a written report was provided to the Company or oral advice was provided
that PricewaterhouseCoopers LLP concluded was an important factor considered by
the Company in reaching a decision as to the accounting, auditing, or financial
reporting issue; or (ii) any matter that was either the subject of a
disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K
and the related instructions to Item 304 of Regulation S-K, or a reportable
event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K.
Item 7. Financial Statements and Exhibits
(c) Exhibits
--------
Exhibit 16.1 Letter from Arthur Andersen LLP to Filed with
The Securities and Exchange this document
Commission dated May 31, 2002
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ALEXION PHARMACEUTICALS, INC.
(registrant)
Date: June 21, 2002 By: /s/ Leonard Bell, M.D.
---------------------------------
Name: Leonard Bell, M.D.
Title: Chief Executive Officer, Secretary
and Treasurer (principal executive
officer)
Date: June 21, 2002 By: /s/ David W. Keiser
----------------------------------
Name: David W. Keiser
Title: President and Chief Operating Officer
(principal financial officer)
Date: June 21, 2002 By: /s/ Barry P. Luke
----------------------------------
Name: Barry P. Luke
Title: Vice President of Finance and
Administration (principal
accounting officer)